Resveratrol attenuates the progress of liver fibrosis via the Akt/nuclear factor-κB pathways

Molecular Medicine Reports

Volumn 13, Issue 1, 2016, Pages 224-230

  Zhang, Hui ^a,b   Sun, Qingfeng ^a   Xu, Tingyan ^a   Hong, Liang ^a   Fu, Rongquan ^a   Wu, Jinguo ^a   Ding, Jiguang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Tianjin Baodi Hospital   (China)

Author keywords

Akt; Hepatic stellate cells; Liver fibrosis; Nuclear factor B; Resveratrol; smooth muscle actin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; I KAPPA B; PROTEIN KINASE B; RESVERATROL; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; ACTA2 PROTEIN, HUMAN; ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STILBENE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL LINE; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ACTINS; ANIMALS; BIOMARKERS; CELL LINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME ACTIVATION; HUMANS; LIVER CIRRHOSIS; MALE; MICE, INBRED C57BL; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STILBENES;

EID: 84954199978     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4497     Document Type: Article

References (30)

1. Moreira RK: Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 131: 1728-1734, 2007.
2. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005.
3. Svegliati-Baroni G, De Minicis S and Marzioni M: Hepatic fibrogenesis in response to chronic liver injury: Novel insights on the role of cell-to-cell interaction and transition. Liver Int 28: 1052-1064, 2008.
4. Hernandez-Gea V and Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol 6: 425-456, 2011.
5. Schuppan D and Kim YO: Evolving therapies for liver fibrosis. J Clin Invest 123: 1887-1901, 2013.
6. Friedman SL: Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7: 425-436, 2010.
7. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006.
8. Bishayee A, Darvesh AS, Politis T and McGory R: Resveratrol and liver disease: From bench to bedside and community. Liver Int 30: 1103-1114, 2010.
9. Bishayee A, Politis T and Darvesh AS: Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 36: 43-53, 2010.
10. Raj P, Louis XL, Thandapilly SJ, Movahed A, Zieroth S and Netticadan T: Potential of resveratrol in the treatment of heart failure. Life Sci 95: 63-71, 2014.
11. Petro TM: Regulatory role of resveratrol on Th17 in autoimmune disease. Int Immunopharmacol 11: 310-318, 2011.
12. Ndiaye M, Philippe C, Mukhtar H and Ahmad N: The grape antioxidant resveratrol for skin disorders: Promise, prospects and challenges. Arch Biochem Biophys 508: 164-170, 2011.
13. Ciddi V and Dodda D: Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies. Pharmacol Rep 66: 799-803, 2014.
14. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR and Kim AL: Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224: 274-283, 2007.
15. Bujanda L, García-Barcina M, Gutiérrez-de Juan V, Bidaurrazaga J, de Luco MF, Gutiérrez-Stampa M, Larzabal M, Hijona E, Sarasqueta C, Echenique-Elizondo M and Arenas JI: Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 6: 35, 2006.
16. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, Kamoun A and El-Fazaâ S: Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci 80: 1033-1039, 2007.
17. Heeboll S, Thomsen KL, Pedersen SB, Vilstrup H, George J and Grønbæk H: Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol 6: 188-198, 2014.
18. Choi YJ, Suh HR, Yoon Y, Lee KJ, Kim DG, Kim S and Lee BH: Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res 37: 1169-1176, 2014.
19. Chavez E, Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Moreno MG and Muriel P: Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J Appl Toxicol 28: 35-43, 2008.
20. Hong SW, Jung KH, Zheng HM, Lee HS, Suh JK, Park IS, Lee DH and Hong SS: The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Res 33: 601-609, 2010.
21. Sener G, Toklu HZ, Sehirli AO, Velioʇlu-Oʇünç A, Cetinel S and Gedik N: Protective effects of resveratrol against acetaminophen-induced toxicity in mice. Hepatol Res 35: 62-68, 2006.
22. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, Gharbi N, Kamoun A and El-Fazaa S: Protective effect of resveratrol on ethanol-induced lipid peroxidation in rats. Alcohol Alcohol 41: 236-239, 2006.
23. Andrade JM, Paraíso AF, de Oliveira MV, Martins AM, Neto JF, Guimarães AL, de Paula AM, Qureshi M and Santos SH: Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 30: 915-919, 2014.
24. Sun B and Karin M: NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 27: 6228-6244, 2008.
25. Abergel A, Sapin V, Dif N, Chassard C, Darcha C, Marcand-Sauvant J, Gaillard-Martinie B, Rock E, Dechelotte P and Sauvant P: Growth arrest and decrease of alpha-SMA and type I collagen expression by palmitic acid in the rat hepatic stellate cell line PAV-1. Dig Dis Sci 51: 986-995, 2006.
26. Luedde T and Schwabe RF: NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8: 108-118, 2011.
27. Wang F, Liu S, Du T, Chen H, Li Z and Yan J: NF-κB inhibition alleviates carbon tetrachloride-induced liver fibrosis via suppression of activated hepatic stellate cells. Exp Ther Med 8: 95-99, 2014.
28. Matsuda S, Kobayashi M and Kitagishi Y: Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol 2013: 472432, 2013.
29. Weichhart T and Süemann MD: The PI3K/Akt/mTOR pathway in innate immune cells: Emerging therapeutic applications. Ann Rheum Dis 67 (Suppl 3): iii70-iii74, 2008.
30. Jackson LN, Larson SD, Silva SR, Rychahou PG, Chen LA, Qiu S, Rajaraman S and Evers BM: PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 294: G1401-G1410, 2008.